News
IPSC
0.5370
+3.27%
0.0170
Weekly Report: what happened at IPSC last week (0428-0502)?
Weekly Report · 5d ago
Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 05/01 12:20
Weekly Report: what happened at IPSC last week (0421-0425)?
Weekly Report · 04/28 09:03
Century Therapeutics: Strategic Advancements and Promising Preclinical Data Justify Buy Rating
TipRanks · 04/24 10:15
Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Intuitive Surgical (ISRG) and Century Therapeutics (IPSC)
TipRanks · 04/23 11:23
Piper Sandler Remains a Buy on Century Therapeutics (IPSC)
TipRanks · 04/23 11:21
Century Therapeutics (IPSC) Gets a Hold from William Blair
TipRanks · 04/22 19:15
Weekly Report: what happened at IPSC last week (0414-0418)?
Weekly Report · 04/21 09:03
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 04/16 12:07
Weekly Report: what happened at IPSC last week (0407-0411)?
Weekly Report · 04/14 09:03
Weekly Report: what happened at IPSC last week (0331-0404)?
Weekly Report · 04/07 09:03
Century Therapeutics Price Target Cut to $2.00/Share From $5.00 by HC Wainwright & Co.
Dow Jones · 04/03 11:09
Century Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/03 11:09
HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $2
Benzinga · 04/03 10:59
Century Therapeutics price target lowered to $2 from $5 at H.C. Wainwright
TipRanks · 04/03 10:16
CENTURY THERAPEUTICS, INC. <IPSC.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $2 FROM $5
Reuters · 04/03 10:06
Weekly Report: what happened at IPSC last week (0324-0328)?
Weekly Report · 03/31 09:03
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 03/28 21:05
Guggenheim Reiterates Buy on Century Therapeuticsto Buy
Benzinga · 03/28 14:43
Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 03/25 16:00
More
Webull provides a variety of real-time IPSC stock news. You can receive the latest news about Century Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About IPSC
More
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.